Table 1 Study population characteristics
Characteristics | Number | SSc-overlap (n = 25) | Number | SSc (n = 397) | Number | PM (n=40) | P value |
|---|---|---|---|---|---|---|---|
Age in years, mean (SD) | 25 | 53 (12.3) | 397 | 50 (13.2) | 40 | 51 (16.5) | 0.013 |
Gender (male/female) | 25 | 12/13 | 397 | 131/266 | 40 | 25/15 | 0.003 |
Type diagnosis | |||||||
Limited cutaneous | 19 (76%) | 276 (73%) | NA | NS | |||
Diffuse cutaneous | 6 (24%) | 109 (27%) | |||||
Disease duration, years median (IQR) | 25 | 5 (3–12) | 397 | 7 (3–14) | 40 | 3.5 (2–11) | 0.001 |
Mortality | 25 | 8 (32%) | 397 | 65 (16%) | 40 | 7 (18%) | NS |
Survival in years, median (IQR) | 8 | 2.5 (1.3-9.6) | 65 | 7 (3–13.5) | 7 | 0.3 (0–12) | NS |
Serology | |||||||
ANA | 25 | 25 (100%) | 397 | 356 (90%) | 34 | 21 (62%) | 0.006 |
Anti-topoisomerase | 21 | 0 | 397 | 87 (22%) | 31 | 1 (3%) | 0.048 |
Anti-centromere | 19 | 2 (10%) | 397 | 76 (19%) | 31 | 0 | NS |
Anti-SSA | 25 | 2 (8%) | 397 | 15 (4%) | 31 | 11 (36%) | < 0.001 |
Anti-SSB | 25 | 0 | NA | 31 | 1 (3%) | NS | |
Anti-RNP | 25 | 2 (8%) | 397 | 27 (7%) | 31 | 2 (6%) | NS |
Anti-SM | 25 | 0 | NA | 31 | 2 (6%) | NS | |
Anti-Jo1 | 25 | 2 (8%) | NA | 31 | 13 (42%) | 0.013 |